Medivation CEO: Positive prostate cancer drug results will transform firm
This article was originally published in Scrip
Executive Summary
With the positive interim results from Medivation's Phase III AFFIRM trial of MDV3100, which showed a 37% reduction in risk of death versus placebo in men with advanced prostate cancer previously treated with chemotherapy – producing a 4.8 month advantage in median overall survival – the San Francisco-based biotech is on the verge of transitioning from a product development firm to a commercialization company, CEO Dr David Hung told Scrip.